MERCURI-2 (2026) — Trial Summary

MERCURI-2 (2026): Multicenter, double-blind, placebo-controlled randomized trial in the Netherlands (2 academic + 5 nonacademic hospitals) of dapagliflozin 10 mg once daily versus placebo for four doses starting the day before elective cardiac surgery through postoperative day 2 (NCT05590143). Prima

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.